A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma

Hidetoshi Eguchi, Yutaka Takeda, Hidenori Takahashi, Shin Nakahira, Masaki Kashiwazaki, Junzo Shimizu, Daisuke Sakai, Fumiaki Isohashi, Hiroaki Nagano, Masaki Mori, Yuichiro Doki

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

Background: Neoadjuvant therapy reportedly shows only marginal clinical benefit in pancreatic ductal adenocarcinoma (PDAC), especially in resectable cases. However, with more effective regimens, neoadjuvant therapy may become a standard of care for resectable cases. A prospective, open-label, multicenter phases 1 and 2 trial of neoadjuvant therapy was conducted using full-dose gemcitabine and S-1 concurrently with 50.4 Gy of radiation therapy (GSRT) for resectable PDAC. This report describes the phase 2 results. Methods: The phase 2 part of this study enrolled 57 patients with cytologically or histologically proven PDAC deemed resectable based on imaging before neoadjuvant therapy. These patients received GSRT. After reevaluation by computed tomography scan, surgical exploration was performed, followed by adjuvant therapy. According to the prescribed protocol of the clinical trial, statistical analyses included 57 phase 2 patients and 6 phase 1 patients who received the same dosage as in phase 2. Results: This trial enrolled 63 patients (42 men and 21 women) with a median age of 70 years. Leukopenia or neutropenia of grade 3 or higher occurred for 79% of the patients, but no other severe adverse events were observed. Among the 63 patients, 54 underwent surgical resection. Intention-to-treat analysis of the 63 patients showed an excellent median survival time lasting as long as 55.3 months. The patients who completed neoadjuvant therapy, surgery, and adjuvant therapy had a 5-year survival rate of 56.6%. Conclusions: This regimen showed outstanding clinical efficacy with acceptable tolerability for patients with resectable PDAC.

元の言語英語
ページ(範囲)4498-4505
ページ数8
ジャーナルAnnals of Surgical Oncology
26
発行部数13
DOI
出版物ステータス出版済み - 12 1 2019

Fingerprint

gemcitabine
Neoadjuvant Therapy
Adenocarcinoma
Radiation
Intention to Treat Analysis
Leukopenia
Standard of Care

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

これを引用

A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma. / Eguchi, Hidetoshi; Takeda, Yutaka; Takahashi, Hidenori; Nakahira, Shin; Kashiwazaki, Masaki; Shimizu, Junzo; Sakai, Daisuke; Isohashi, Fumiaki; Nagano, Hiroaki; Mori, Masaki; Doki, Yuichiro.

:: Annals of Surgical Oncology, 巻 26, 番号 13, 01.12.2019, p. 4498-4505.

研究成果: ジャーナルへの寄稿記事

Eguchi, Hidetoshi ; Takeda, Yutaka ; Takahashi, Hidenori ; Nakahira, Shin ; Kashiwazaki, Masaki ; Shimizu, Junzo ; Sakai, Daisuke ; Isohashi, Fumiaki ; Nagano, Hiroaki ; Mori, Masaki ; Doki, Yuichiro. / A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma. :: Annals of Surgical Oncology. 2019 ; 巻 26, 番号 13. pp. 4498-4505.
@article{1b3341ea9bd94ffca684cd8e87b4a519,
title = "A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma",
abstract = "Background: Neoadjuvant therapy reportedly shows only marginal clinical benefit in pancreatic ductal adenocarcinoma (PDAC), especially in resectable cases. However, with more effective regimens, neoadjuvant therapy may become a standard of care for resectable cases. A prospective, open-label, multicenter phases 1 and 2 trial of neoadjuvant therapy was conducted using full-dose gemcitabine and S-1 concurrently with 50.4 Gy of radiation therapy (GSRT) for resectable PDAC. This report describes the phase 2 results. Methods: The phase 2 part of this study enrolled 57 patients with cytologically or histologically proven PDAC deemed resectable based on imaging before neoadjuvant therapy. These patients received GSRT. After reevaluation by computed tomography scan, surgical exploration was performed, followed by adjuvant therapy. According to the prescribed protocol of the clinical trial, statistical analyses included 57 phase 2 patients and 6 phase 1 patients who received the same dosage as in phase 2. Results: This trial enrolled 63 patients (42 men and 21 women) with a median age of 70 years. Leukopenia or neutropenia of grade 3 or higher occurred for 79{\%} of the patients, but no other severe adverse events were observed. Among the 63 patients, 54 underwent surgical resection. Intention-to-treat analysis of the 63 patients showed an excellent median survival time lasting as long as 55.3 months. The patients who completed neoadjuvant therapy, surgery, and adjuvant therapy had a 5-year survival rate of 56.6{\%}. Conclusions: This regimen showed outstanding clinical efficacy with acceptable tolerability for patients with resectable PDAC.",
author = "Hidetoshi Eguchi and Yutaka Takeda and Hidenori Takahashi and Shin Nakahira and Masaki Kashiwazaki and Junzo Shimizu and Daisuke Sakai and Fumiaki Isohashi and Hiroaki Nagano and Masaki Mori and Yuichiro Doki",
year = "2019",
month = "12",
day = "1",
doi = "10.1245/s10434-019-07735-8",
language = "English",
volume = "26",
pages = "4498--4505",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "13",

}

TY - JOUR

T1 - A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma

AU - Eguchi, Hidetoshi

AU - Takeda, Yutaka

AU - Takahashi, Hidenori

AU - Nakahira, Shin

AU - Kashiwazaki, Masaki

AU - Shimizu, Junzo

AU - Sakai, Daisuke

AU - Isohashi, Fumiaki

AU - Nagano, Hiroaki

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Background: Neoadjuvant therapy reportedly shows only marginal clinical benefit in pancreatic ductal adenocarcinoma (PDAC), especially in resectable cases. However, with more effective regimens, neoadjuvant therapy may become a standard of care for resectable cases. A prospective, open-label, multicenter phases 1 and 2 trial of neoadjuvant therapy was conducted using full-dose gemcitabine and S-1 concurrently with 50.4 Gy of radiation therapy (GSRT) for resectable PDAC. This report describes the phase 2 results. Methods: The phase 2 part of this study enrolled 57 patients with cytologically or histologically proven PDAC deemed resectable based on imaging before neoadjuvant therapy. These patients received GSRT. After reevaluation by computed tomography scan, surgical exploration was performed, followed by adjuvant therapy. According to the prescribed protocol of the clinical trial, statistical analyses included 57 phase 2 patients and 6 phase 1 patients who received the same dosage as in phase 2. Results: This trial enrolled 63 patients (42 men and 21 women) with a median age of 70 years. Leukopenia or neutropenia of grade 3 or higher occurred for 79% of the patients, but no other severe adverse events were observed. Among the 63 patients, 54 underwent surgical resection. Intention-to-treat analysis of the 63 patients showed an excellent median survival time lasting as long as 55.3 months. The patients who completed neoadjuvant therapy, surgery, and adjuvant therapy had a 5-year survival rate of 56.6%. Conclusions: This regimen showed outstanding clinical efficacy with acceptable tolerability for patients with resectable PDAC.

AB - Background: Neoadjuvant therapy reportedly shows only marginal clinical benefit in pancreatic ductal adenocarcinoma (PDAC), especially in resectable cases. However, with more effective regimens, neoadjuvant therapy may become a standard of care for resectable cases. A prospective, open-label, multicenter phases 1 and 2 trial of neoadjuvant therapy was conducted using full-dose gemcitabine and S-1 concurrently with 50.4 Gy of radiation therapy (GSRT) for resectable PDAC. This report describes the phase 2 results. Methods: The phase 2 part of this study enrolled 57 patients with cytologically or histologically proven PDAC deemed resectable based on imaging before neoadjuvant therapy. These patients received GSRT. After reevaluation by computed tomography scan, surgical exploration was performed, followed by adjuvant therapy. According to the prescribed protocol of the clinical trial, statistical analyses included 57 phase 2 patients and 6 phase 1 patients who received the same dosage as in phase 2. Results: This trial enrolled 63 patients (42 men and 21 women) with a median age of 70 years. Leukopenia or neutropenia of grade 3 or higher occurred for 79% of the patients, but no other severe adverse events were observed. Among the 63 patients, 54 underwent surgical resection. Intention-to-treat analysis of the 63 patients showed an excellent median survival time lasting as long as 55.3 months. The patients who completed neoadjuvant therapy, surgery, and adjuvant therapy had a 5-year survival rate of 56.6%. Conclusions: This regimen showed outstanding clinical efficacy with acceptable tolerability for patients with resectable PDAC.

UR - http://www.scopus.com/inward/record.url?scp=85071525875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071525875&partnerID=8YFLogxK

U2 - 10.1245/s10434-019-07735-8

DO - 10.1245/s10434-019-07735-8

M3 - Article

C2 - 31440928

AN - SCOPUS:85071525875

VL - 26

SP - 4498

EP - 4505

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 13

ER -